title: Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.
authors.affiliation: Division of Rheumatology, Itabashi Chuo Medical Center, 2-12-7 Azusawa, Itabashi-ku, Tokyo 174-0051, Japan.
authors.forename: Isamu
authors.initials: I
authors.lastname: Yokoe
authors.forename: Shinya
authors.initials: S
authors.lastname: Nishio
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sato
authors.forename: Hitomi
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000097:blood*; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3; C502936:tocilizumab